

Transforming the adjuvant treatment paradigm in melanoma

**Saturday,
18 September 2021**

08:45 – 10:15 (CEST)
Channel 4

Chair



Alexander Eggermont

Eur J Cancer Editor in Chief
Chief Scientific Officer
Board of Directors
Professor, Clinical and
Translational Immunotherapy
UMCU, Utrecht University
Utrecht, Netherlands

Faculty



Paolo Ascierto

Melanoma, Cancer
Immunotherapy and
Development Therapeutics Unit
Istituto Nazionale Tumori
IRCCS Fondazione “G. Pascale”
Naples, Italy



Axel Hauschild

Professor and Head
Dermato-Oncology Department
University of Kiel
Kiel, Germany



John Kirkwood

Distinguished Service
Professor of Medicine
University of Pittsburgh
Usher Professor of Medicine,
Dermatology and Translational
Science
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, USA



Jason Luke

Associate Professor of Medicine
Division of Hematology/Oncology
University of Pittsburgh
Director, Cancer
Immunotherapeutic Center
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, USA

Agenda

08:45 – 08:50	Welcome and introductions <i>Alexander Eggermont</i>
08:50 – 09:05	Historical adjuvant treatment of melanoma: Have we made a difference? <i>John Kirkwood</i>
09:05 – 09:35	Debate: High-risk, early-stage melanoma patients should be treated with systemic adjuvant therapy? No <i>Paolo Ascierto</i> Yes <i>Axel Hauschild</i>
09:35 – 09:50	Adjuvant treatment of high-risk melanoma: What is the future? <i>Jason Luke</i>
09:50 – 10:10	Panel discussion and Q&A <i>All faculty</i>
10:10 – 10:15	Closing remarks <i>Alexander Eggermont</i>

Satellite Symposium sponsored by MSD

